Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Ladanyi
    Ladanyi
  2. Arcila
    Arcila
  3. Berger
    Berger
  4. Nafa
    Nafa
  5. Razavi
    Razavi
  6. Ross
    Ross
  7. Aghajanian
    Aghajanian
  8. Chang
    Chang
  9. Drilon
    Drilon
  10. Janjigian
    Janjigian

Groups

  1. Department of Medicine (4)
  2. Early Drug Development Service (4)
  3. Solid Tumor Oncology Division (4)
  4. GSK Faculty (3)
  5. Human Oncology and Pathogenesis Program (3)
  6. Tow Center for Developmental Oncology (TCDO) (3)
  7. Breast Medicine Service (2)
  8. Gynecology Disease Management Team (2)
  9. Center for Pancreatic Cancer Research (1)
  10. GDMT, Medicine (1)
Search Within
  1. "Early Drug Development Service"
  2. "Journal article"
Formats
  1. Journal Article (4)
Groups
  1. Department of Medicine (4)
  2. Early Drug Development Service (4)
  3. Solid Tumor Oncology Division (4)
  4. GSK Faculty (3)
  5. Human Oncology and Pathogenesis Program (3)
  6. Tow Center for Developmental Oncology (TCDO) (3)

More Groups

People
  1. David Hyman (4)
  2. Marc Ladanyi (3)
  3. Ahmet Zehir (2)
  4. Dara Ross (2)
  5. Jose Baselga (2)
  6. Khedoudja Nafa (2)

More People

Years
  1. 2020 (1)
  2. 2019 (2)
  3. 2017 (1)
Publications
  1. Journal of Molecular Diagnostics (2)
  2. Lancet Oncology (2)

Results (4)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials
    Journal Article

    Hong, D. S.; DuBois, S. G.; Kummar, S.; Farago, A. F.; Albert, C. M.; Rohrberg, K. S.; van Tilburg, C. M.; Nagasubramanian, R.; Berlin, J. D.; Federman, N.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: An interim analysis of a multicentre, open-label, single-arm, phase 2 trial
    Journal Article

    Makker, V.; Rasco, D.; Vogelzang, N. J.; Brose, M. S.; Cohn, A. L.; Mier, J.; Di Simone, C.; Hyman, D. M.; Stepan, D. E.; Dutcus, C. E.; more...
    Lancet Oncology (2019)

    Fulltext@MSK | Save
  • Next-generation sequencing–based assessment of JAK2, PD-L1, and PD-L2 copy number alterations at 9p24.1 in breast cancer: Potential implications for clinical management
    Journal Article

    Gupta, S.; Vanderbilt, C. M.; Cotzia, P.; Arias-Stella, J. A. 3rd; Chang, J. C.; Zehir, A.; Benayed, R.; Nafa, K.; Razavi, P.; Hyman, D. M.; more...
    Journal of Molecular Diagnostics (2019)

    Fulltext@MSK | Save
  • Next-generation assessment of human growth factor receptor 2 (ERBB2) amplification status: Clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay
    Journal Article

    Ross, D. S.; Zehir, A.; Cheng, D. T.; Benayed, R.; Nafa, K.; Hechtman, J. F.; Janjigian, Y. Y.; Weigelt, B.; Razavi, P.; Hyman, D. M.; more...
    Journal of Molecular Diagnostics (2017)

    Fulltext@MSK | Save